Skip to content

Study · Animal study (in vivo) · rat · 2001

13 results

Skeletal growth acceleration with growth hormone secretagogues in transgenic growth retarded rats: pattern-dependent effects and mechanisms of desensitization.

Wells T, Houston PA

Journal of neuroendocrinology1 Jun 2001Cited by 22 (Europe PMC)

PMID11412336 (opens in a new tab)DOI10.1046/j.1365-2826.2001.00661.x (opens in a new tab)PepBankPUB-11412336
Publisher pagePubMedAsk about this study
Jump to 13 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study13

10 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In growth-retarded rats, GHRP‑6 accelerated skeletal growth with dose- and pattern-dependent effects.

    In plain wordsIn growth-retarded rats, GHRP‑6 increased skeletal growth, with effects that depended on dose and delivery pattern.

    Peptide
    GHRP-6
    Outcome
    IncreaseSkeletal growth
    Study

    ratn: not reported in source

    transgenic growth retarded rats
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We have confirmed that GHS-induced elevation in body weight gain was accompanied by acceleration of skeletal growth, and that the effects of the GHS, GHRP-6, were both dose- and pattern-dependent.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In growth-retarded rats, continuous GHRP‑6 infusion produced a transient growth response.

    In plain wordsIn growth-retarded rats, continuous GHRP‑6 infusion increased growth only temporarily.

    Peptide
    GHRP-6
    Outcome
    IncreaseGrowth with continuous infusion
    Study

    ratn: not reported in source

    transgenic growth retarded rats
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The growth response with continuous infusion of GHRP-6 was transient, accompanied by suppression of GH and corticosterone responses to bolus injection of GHRP-6.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In growth-retarded rats, continuous GHRP‑6 infusion suppressed GH responses to bolus GHRP‑6.

    In plain wordsIn growth-retarded rats, continuous GHRP‑6 reduced growth hormone responses to a GHRP‑6 bolus.

    Peptide
    GHRP-6
    Outcome
    DecreaseGH response with continuous infusion
    Study

    ratn: not reported in source

    transgenic growth retarded rats
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The growth response with continuous infusion of GHRP-6 was transient, accompanied by suppression of GH and corticosterone responses to bolus injection of GHRP-6.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In growth-retarded rats, continuous GHRP‑6 infusion suppressed corticosterone responses to bolus GHRP‑6.

    In plain wordsIn growth-retarded rats, continuous GHRP‑6 reduced corticosterone responses to a GHRP‑6 bolus.

    Peptide
    GHRP-6
    Outcome
    DecreaseCorticosterone response with continuous infusion
    Study

    ratn: not reported in source

    transgenic growth retarded rats
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The growth response with continuous infusion of GHRP-6 was transient, accompanied by suppression of GH and corticosterone responses to bolus injection of GHRP-6.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In growth-retarded rats, desensitization during continuous GHRP‑6 treatment occurred without reduced arcuate GHS-R mRNA.

    In plain wordsIn growth-retarded rats, continuous GHRP‑6 desensitization did not involve reduced arcuate receptor gene expression.

    Peptide
    GHRP-6
    Outcome
    No significant changeArcuate GHS-R mRNA with continuous infusion
    Study

    ratn: not reported in source

    transgenic growth retarded rats
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    This desensitization occurred without downregulation of arcuate GHS-R mRNA expression, but was accompanied by elevated periventricular somatostatin mRNA expression.
    1 context sentence
    Summary · context
    The growth response with continuous infusion of GHRP-6 was transient, accompanied by suppression of GH and corticosterone responses to bolus injection of GHRP-6.
  6. 06AnimalAnimal study (in vivo)Mechanism

    In growth-retarded rats, continuous GHRP‑6 desensitization accompanied elevated periventricular somatostatin mRNA.

    In plain wordsIn growth-retarded rats, continuous GHRP‑6 desensitization accompanied increased somatostatin gene expression.

    Peptide
    GHRP-6
    Outcome
    IncreasePeriventricular somatostatin mRNA
    Study

    ratn: not reported in source

    transgenic growth retarded rats
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    This desensitization occurred without downregulation of arcuate GHS-R mRNA expression, but was accompanied by elevated periventricular somatostatin mRNA expression.
    1 context sentence
    Summary · context
    The growth response with continuous infusion of GHRP-6 was transient, accompanied by suppression of GH and corticosterone responses to bolus injection of GHRP-6.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In growth-retarded rats, pulsatile GHRP‑6 infusion produced sustained growth responses.

    In plain wordsIn growth-retarded rats, pulsatile GHRP‑6 produced sustained growth responses.

    Peptide
    GHRP-6
    Outcome
    IncreaseGrowth with pulsatile infusion
    Study

    ratn: not reported in source

    transgenic growth retarded rats
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In contrast, pulsatile (3-hourly) infusion of GHRP-6 produced sustained growth and GH responses, which were accompanied by suppression of corticosterone responses and elevated arcuate GH-releasing factor (GRF) mRNA expression.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In growth-retarded rats, pulsatile GHRP‑6 infusion produced sustained GH responses.

    In plain wordsIn growth-retarded rats, pulsatile GHRP‑6 produced sustained growth hormone responses.

    Peptide
    GHRP-6
    Outcome
    IncreaseGH response with pulsatile infusion
    Study

    ratn: not reported in source

    transgenic growth retarded rats
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In contrast, pulsatile (3-hourly) infusion of GHRP-6 produced sustained growth and GH responses, which were accompanied by suppression of corticosterone responses and elevated arcuate GH-releasing factor (GRF) mRNA expression.
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In growth-retarded rats, pulsatile GHRP‑6 infusion suppressed corticosterone responses.

    In plain wordsIn growth-retarded rats, pulsatile GHRP‑6 reduced corticosterone responses.

    Peptide
    GHRP-6
    Outcome
    DecreaseCorticosterone response with pulsatile infusion
    Study

    ratn: not reported in source

    transgenic growth retarded rats
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In contrast, pulsatile (3-hourly) infusion of GHRP-6 produced sustained growth and GH responses, which were accompanied by suppression of corticosterone responses and elevated arcuate GH-releasing factor (GRF) mRNA expression.
  10. 10AnimalAnimal study (in vivo)Mechanism

    In growth-retarded rats, pulsatile GHRP‑6 infusion elevated arcuate GRF mRNA expression.

    In plain wordsIn growth-retarded rats, pulsatile GHRP‑6 increased arcuate GRF gene expression.

    Peptide
    GHRP-6
    Outcome
    IncreaseArcuate GRF mRNA
    Study

    ratn: not reported in source

    transgenic growth retarded rats
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In contrast, pulsatile (3-hourly) infusion of GHRP-6 produced sustained growth and GH responses, which were accompanied by suppression of corticosterone responses and elevated arcuate GH-releasing factor (GRF) mRNA expression.

Studies that did not test the peptide alone3

In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-6.

  1. 11AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Efficacy outcome

    In growth-retarded rats, secretagogues including GHRP‑6 increased body weight gain.

    In plain wordsIn growth-retarded rats, secretagogues including GHRP‑6 increased weight gain.

    Peptide
    GHRP-6
    Outcome
    IncreaseBody weight gain
    Study

    ratn: not reported in source

    transgenic growth retarded rats
    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    We have confirmed that GHS-induced elevation in body weight gain was accompanied by acceleration of skeletal growth, and that the effects of the GHS, GHRP-6, were both dose- and pattern-dependent.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

  2. 12AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Efficacy outcome

    In growth-retarded rats, adding GRF to GHRP‑6 infusion further accelerated skeletal growth.

    In plain wordsIn growth-retarded rats, GHRP‑6 with GRF increased skeletal growth more than GHRP‑6 infusion alone.

    Peptide
    GHRP-6
    Outcome
    IncreaseSkeletal growth with GRF coinfusion
    Study

    ratn: not reported in source

    transgenic growth retarded rats
    Comparator
    GHRP-6 infusion
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    Skeletal growth was further accelerated by coinfusion of GRF, but significant depletion of pituitary GH stores suggested that this growth rate may not be sustainable.
    1 context sentence
    Summary · context
    In contrast, pulsatile (3-hourly) infusion of GHRP-6 produced sustained growth and GH responses, which were accompanied by suppression of corticosterone responses and elevated arcuate GH-releasing factor (GRF) mRNA expression.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

  3. 13AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Efficacy outcome

    In growth-retarded rats, GHRP‑6 with GRF coinfusion significantly depleted pituitary GH stores.

    In plain wordsIn growth-retarded rats, GHRP‑6 with GRF depleted pituitary growth hormone stores.

    Peptide
    GHRP-6
    Outcome
    DecreasePituitary GH stores with GRF coinfusion
    Study

    ratn: not reported in source

    transgenic growth retarded rats
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    Skeletal growth was further accelerated by coinfusion of GRF, but significant depletion of pituitary GH stores suggested that this growth rate may not be sustainable.
    1 context sentence
    Summary · context
    In contrast, pulsatile (3-hourly) infusion of GHRP-6 produced sustained growth and GH responses, which were accompanied by suppression of corticosterone responses and elevated arcuate GH-releasing factor (GRF) mRNA expression.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.